Figure 6.

Antitumor activity of BsAb5003 against KMS-26 tumors in NSG mice inoculated with human T cells. (a) Each mouse received the SC injection of 3 × 10⁶ KMS-26 cells into the left flank on day 0. Ten days later, mice were injected IV with 1 × 10⁷ human T cells, followed by IV administration of PBS as a control or BsAb5003 antibody at 0.003 mg/kg, 0.01 mg/kg, 0.03 mg/kg or 0.1 mg/kg on days 10 and 17. (b) Tumor size was measured twice a week. Each plot indicates mean ± standard error of estimated tumor volume (n = 6). Statistical significance between the control group and treatment groups with 0.01 mg/kg, 0.03 mg/kg, and 0.1 mg/kg BsAb5003 at day 21 was assessed using parametric Dunnett's test (**P < 0.01). (c) For IHC staining, mice were sacrificed by carbon dioxide inhalation on day 24 and the tumors were obtained. Representative images of CD3 IHC in control mouse (left) and mouse treated with 0.03 mg/kg BsAb5003 are shown.